The global vascular graft market is driven by increase in the incidence of vascular disorders, high blood glucose level, hypertension, and other risk factors that cause blockage of blood vessels. The global vascular grafts market was valued at $4,192 million in 2016, and is expected to reach at $6,218 million by 2023, growing at a CAGR of 5.7% from 2017 to 2023. In addition, sedentary lifestyle, rise in geriatric population, and technological advancements supplement the market growth. However, high cost of treatment and increase in complications associated with prosthetic grafts restrain the market growth. Conversely, rise in awareness for vascular grafts and huge market opportunities in the emerging economies of Asia-Pacific and LAMEA regions are expected to provide numerous opportunities to the market players in the near future.
The global vascular graft market is segmented on the basis of product, raw material, end user, and region. On the basis of product, it is classified into endovascular stent graft, peripheral vascular graft, and hemodialysis access graft. The endovascular stent graft segment is bifurcated into abdominal aortic aneurysm (AAA) and thoracic aortic aneurysm (TAA). On the basis of raw material, it is categorized into polyester, polytetrafluoroethylene (PTFE), polyurethane, and biosynthetic. Based on end user, it is divided into hospitals & ambulatory surgical centers. The market is analyzed based on region into North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis of the market from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
Comprehensive analyses of the product type and raw materials help in understanding the regional trends and potential investment areas.
Key market players and their strategies have been thoroughly analyzed to understand the competitive outlook of the industry.
KEY MARKET SEGMENTS
Hemodialysis Access Graft
Endovascular Aneurysm Repair Stent Grafts
Abdominal Aortic Aneurysm (AAA)
Thoracic Aortic Aneurysm (TAA)
Peripheral Vascular Graft
By Raw Material
By End User
Ambulatory Surgical Centers
Rest of Europe
Rest of Asia-Pacific
Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
B. Braun Melsungen AG
C. R. Bard Inc.
Cardinal Health Inc.
Cook Medical Inc.
LeMaitre Vascular Inc.
MAQUET Holding B.V. & Co. KG (a Getinge Group Company)
W. L. Gore & Associates Inc.
List of the other players in the value chain (these players are not profiled in the report, the same can be included on request)
Lombard Medical Inc.
Japan Lifeline Co. Ltd.
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
22.214.171.124. Competitive intelligence of companies and their strategies
3.3. TOP PLAYER POSITIONING, 2016
3.4. MARKET DYNAMICS
126.96.36.199. Rise in incidence of risk factors that lead to blockage of blood vessels
188.8.131.52. Increase in geriatric population
184.108.40.206. Technological advancements
220.127.116.11. Lifestyle changes leading to blockage of blood vessels
18.104.22.168. High cost of treatment
22.214.171.124. Complications associated with prosthetic grafts
126.96.36.199. Growth opportunities in emerging markets
188.8.131.52. Increase in awareness for vascular grafts
3.4.4. Impact analysis
3.5. CLINICAL TRIALS
CHAPTER 4 GLOBAL VASCULAR GRAFT MARKET, BY TYPE
4.1.1. Market size and forecast
4.2. HEMODIALYSIS ACCESS GRAFT
4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.3. ENDOVASCULAR ANEURYSM REPAIR STENT GRAFTS
4.3.1. Abdominal Aortic Aneurysm (AAA)
4.3.2. Thoracic Aortic Aneurysm (TAA)
4.3.3. Key market trends
4.3.4. Key growth factors and opportunities
4.3.5. Market size and forecast
4.4. PERIPHERAL VASCULAR GRAFT
4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast
CHAPTER 5 VASCULAR GRAFT MARKET, BY RAW MATERIAL
5.1.1. Market size and forecast
5.2.1. Market size and forecast
5.3. POLYTETRAFLUOROETHYLENE (PTFE)
5.3.1. Market size and forecast
5.4.1. Market size and forecast
5.5.1. Market size and forecast
CHAPTER 6 VASCULAR GRAFT MARKET, BY END USER
6.1.1. Market size and forecast
6.2.1. Market size and forecast
6.3. AMBULATORY SURGICAL CENTERS (ASCS)
6.3.1. Market size and forecast
CHAPTER 7 VASCULAR GRAFT MARKET, BY REGION
7.1.1. Market size and forecast
7.2. NORTH AMERICA
7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.9. Rest of Europe
7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast
7.4.7. South Korea
7.4.9. Rest of Asia-Pacific
7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast
7.5.5. South Africa
7.5.6. Saudi Arabia
7.5.7. Rest of LAMEA
CHAPTER 8 COMPANY PROFILES
8.1. B. BRAUN MELSUNGEN AG
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.8. Key strategic moves and developments
8.2. C. R. BARD, INC.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Key strategic moves and developments
8.3. CARDINAL HEALTH INC.
8.3.1. Company overview
8.3.2. Company Snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.8. Key strategic moves and developments
8.4. COOK MEDICAL INC.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Key strategic moves and developments
8.5. ENDOLOGIX INC.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.8. Key strategic moves and developments
8.6. LEMAITRE VASCULAR, INC.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.8. Key strategic moves and developments
8.7. MAQUET HOLDING B.V. & CO. KG
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Key strategic moves and developments
8.8. MEDTRONIC PLC
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Key strategic moves and developments
8.9. TERUMO CORPORATION
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating product categories
8.9.4. Product portfolio
8.9.5. Business performance
8.9.8. Key strategic moves and developments
8.10. W. L. GORE & ASSOCIATES, INC.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
Vascular grafts are medical devices that are used in surgical procedures to redirect blood flow from one area to another by reconnecting blood vessels. Vascular graft surgery is performed in patients with blocked arteries to restore normal blood flow within the body. Increase in incidence of lifestyle-related disorders has fueled the demand for vascular grafts.
The global vascular grafts market is driven by increase in the prevalence of vascular disorders, high blood glucose level, hypertension, and other risk factors that cause blockage of blood vessels. In addition, sedentary lifestyle, growth in geriatric population, and technological advancements are expected to supplement the market growth during the forecast period. However, increased cost of treatment and complications associated with prosthetic grafts impede the market growth. Conversely, rise in awareness for vascular grafts and huge market opportunities in the emerging economies of Asia-Pacific and LAMEA regions are expected to provide several opportunities to the key market players during the forecast period.
The endovascular aneurysm repair stent grafts segment is expected to maintain its dominant position during the forecast period, owing to the associated benefits of being a minimally invasive procedure as compared to open-chest or open-abdominal aneurysm surgery. This has boosted endovascular aneurysm repair stent grafts market, as the total time required for the surgery is reduced by several days.
The biosynthetic raw material segment is expected to grow at a CAGR of 6.5% during the forecast period, owing to the combination of properties of both synthetic as well as biological materials, which give optimal results.
Key Findings of the Vascular Grafts Market:
The polytetrafluoroethylene (PTFE) segment accounted for more than half of the raw materials market share in 2016.
The endovascular aneurysm repair stent grafts segment accounted for nearly three-fifths share of the global market in 2016, and is expected to grow at a CAGR of 6.2% from 2017 to 2023.
The hospitals segment accounted for more than half of the end users share in 2016.
Asia-Pacific is expected to grow at the highest CAGR of 7.5% from 2017 to 2023.
North America accounted for a major share (more than half) in the global market in 2016, and is expected to maintain its dominance throughout the forecast period, owing to the increase in incidence of vascular disorders & renal diseases and rise in patient awareness about the benefits of vascular graft surgery. In addition, high adoption rate of technologically advanced devices and presence of highly sophisticated healthcare infrastructures are expected to offer new growth opportunities to the players in the market.
- B. Braun Melsungen AG
- C. R. Bard Inc.
- Cardinal Health Inc.
- Cook Medical Inc.
- Endologix Inc.
- LeMaitre Vascular Inc.
- MAQUET Holding B.V. & Co. KG (a Getinge Group Company)
- Medtronic plc.
- Terumo Corporation
- W. L. Gore & Associates Inc.